Company Filing History:
Years Active: 2008-2013
Title: Innovations by Jesús Jiménez López
Introduction
Jesús Jiménez López is a notable inventor based in Granada, Spain. He has made significant contributions to the field of microbiology, particularly in the development of probiotic microorganisms derived from mammalian milk. His work focuses on innovative solutions for the prevention and treatment of mastitis in both humans and animals.
Latest Patents
Jesús Jiménez López holds 2 patents that showcase his innovative approaches. His first patent, titled "Mammalian milk microorganisms, compositions containing them and their use for the treatment of mastitis," presents a novel method to prevent or treat mastitis using milk-derived microorganisms from healthy hosts. This invention emphasizes the use of probiotic microorganisms to reduce infectious mastitis and outlines the methods for their screening and application.
The second patent, "Probiotic strains, a process for the selection of them, compositions thereof, and their use," details a unique process for selecting non-pathogenic probiotic strains that can survive in breast milk and amniotic fluid. This invention also introduces new strains and their potential applications in treating various diseases, including digestive, infectious, neuro-degenerative, and immune-related conditions.
Career Highlights
Throughout his career, Jesús has worked with reputable companies such as Puleva Biotech and Biosearch. His experience in these organizations has allowed him to further develop his expertise in microbiology and probiotic research.
Collaborations
Jesús has collaborated with notable individuals in his field, including Julio Boza Puerta and Jordi Xaus Pei. These partnerships have contributed to the advancement of his research and the successful development of his patents.
Conclusion
Jesús Jiménez López is a pioneering inventor whose work in probiotic microorganisms has the potential to revolutionize the treatment of mastitis and other related diseases. His innovative patents and collaborations highlight his commitment to advancing microbiological research and improving health outcomes.